CIP
LXRX icon

Convergence Investment Partners’s Lexicon Pharmaceuticals LXRX Stock Holding History

Convergence Investment Partners’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-45,279
Closed -$818K – 353
2016
Q3 		$818K Sell
45,279
-68,878
-60% -$1.11M 0.12% 253
2016
Q2 		$1.64M Buy
+114,157
New +$1.55M 0.23% 169

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Convergence Investment Partners's LXRX Position: Q4 2016 in Review

Convergence Investment Partners sold out of Lexicon Pharmaceuticals (LXRX) in Q4 2016, closing a stake of 45,279 shares — an estimated $818K sold.

Convergence Investment Partners first reported a position in LXRX in Q2 2016 and held it in 2 quarters. The position peaked at $1.64M in Q2 2016. 146 funds tracked by Wall St. Rank hold LXRX as of Q4 2016.

  • Convergence Investment Partners reported no remaining Lexicon Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Convergence Investment Partners sold 45,279 Lexicon Pharmaceuticals shares in Q4 2016, an estimated $818K.
  • Convergence Investment Partners first reported a position in Lexicon Pharmaceuticals in Q2 2016 and held it in 2 quarters.
  • Convergence Investment Partners's Lexicon Pharmaceuticals position peaked at $1.64M in Q2 2016.
  • 146 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2016.

Based on Convergence Investment Partners's 13F filing for Q4 2016, filed 13 Feb 2017.